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Dysbiosis in MS patients has been
constantly observed in several
studies, with subtle changes in the
relative abundance of some specific
bacterial genera.
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Figure 2. Profile of gut microbiota in MS patients. The diagram summarizes the changes identified
in 4 studies (Jangi S et al (2016), Chen J et al (2016), Miyake S et al (2015) and Cekanaviciute E et al
(2017)). rRNA: ribosomal RNA; RRMS: Relapse-remitting multiple sclerosis.
Aims
▪ To describe the profile of gut microbiota in patients
with MS.
▪ To determine the role of CNS-intrinsic cells
(microglia and astrocytes) in MS pathogenesis.
▪ To analyse the interaction between microbiome
and CNS-resident cells, emphasising in dietary
tryptophan metabolites and short-fatty chain acids.
▪ To study its consequences in regards to the
neuroinflammation present in MS.
Neuroinflammation is a hallmark of multiple
sclerosis (MS), in which microglia and
astrocytes are key players. Given the
multifactorial etiology, gut dysbiosis has
emerged as a potential pathogenic factor.
Despite being extensively studied how
microbial immunomodulatory metabolites
impact on T-lymphocytes, less is known
about the effects on microglial and
astrocytic activity and the consequences
on neuroinflammation.
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Figure 4. Enhancement of neuroinflammation in MS due to low tryptophan metabolites levels, promoting the secretion of proinflammatory cytokines, chemokines
and neurotoxic factors from astrocytes and microglia directly and also indirectly, through the modulation of the ratio VEGFB/TFGα in microglia. TGFα: Transforming growth
factor alpha; VEGFB: Vascular endothelial growth factor B; Flt1: Fms related tyrosine kinase 1; NF-κB: Nuclear factor kappa b; CSF: Colony-stimulating factor.
Dietary tryptophan metabolites (indoles and other derivatives) act as aryl hydrocarbon receptor
(AHR) ligands. In MS patients, circulating levels of AHR agonists are lower in comparison with
control individuals. As a consequence, their capability to reduce the proinflammatory phenotype
of microglia and astrocytes is impaired and neuroinflammation and MS are worsened.
Short-chain fatty acids (SCFAs) are immunomodulatory metabolites. In
MS patients, circulating levels of SCFAs are decreased as a
consequence of the dysbiosis. SCFAs are important in the modulation of
microglia maturation and function; however, little is known about the
consequences on neuroinflammation in MS.
Figure 5. Alteration of microglia maturation owing to SCFAs levels’ reduction, even
though the consequences on MS progression have not been described.
CSFR: Colony stimulating factor receptor; PPAR: Peroxisome proliferator-activated receptor
▪ Search on Pubmed database.
▪ Keywords (alone or in combination): “microbiota”,
“dysbiosis”, “multiple sclerosis”, “microglia”,
“astrocytes”, “tryptophan metabolites”, “SCFAs”.
▪ Selection criteria: Journal impact factor, date of
publication (last 5 years) and relation with the
review topic.
▪ Reading and summary of the selected articles;
exhaustive analysis of their bibliography.
Figure 3. Dual role of microglia and astrocytes in MS. CNS-resident cells, mainly microglia and astrocytes, are key players in neuroinflammation. They have a dual
role in MS, being their activity favourable or damaging, depending on the stage of the disease.
BDNF: Brain-derived neurotrophic factor; IGF: Insulin growth factor; MHCII: Major histocompatibility complex II; TNFα: Tumor necrosis factor alpha; CCL: chemokine (C-
C motif) ligand; CXCL: chemokine (C-X-C motif) ligand; IL: interleukin: iNOS: inducible nitric oxide synthase; BBB: Brain-blood barrier
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Whereas in the disease onset neuroprotective M2 microglia and A2 astrocytes promote axonal regeneration and remyelination,
their neurotoxic and demyelinating properties predominate to the extent that the disease progresses due to a shift to
proinflammatory M1 microglia and reactive A1 astrocytes.
A generalized “MS microbiota
phenotype” has not been described,
suggesting that many factors can
influence its composition (e.g. age,
diet, geographical features). Beneficial effect
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Figure 1. Diagram of MS pathogenesis. OG: Oligodendrocyte; SCFAs:
Short-chain fatty acids; Trp: Tryptophan.
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▪ Gut dysbiosis may predispose or modify the course of MS.
▪ The functional relevance of the interaction between CNS-resident cells and microbiome in MS pathogenesis remains unknown.
▪ Given the pathogenic role of microglia and astrocytes, determining the specific mechanisms by which gut microbiota, astrocytes and
microglia interact may be relevant to develop new therapeutic approaches.
▪ Most studies have used EAE model or RRMS patients. Studies of gut microbiota in patients with progressive MS may reveal possible
other changes in microbial populations.
▪ It can be extrapolated to other neurodegenerative disease where a dysbiosis has been identified (e.g. Parkinson or Alzheimer diseases).
A2 astrocytesM2 microglia
1 Support to remyelination
2
Removal of inhibitory myelin debris and
apoptotic oligodendrocytes
3
Promotion of axonal regeneration:
neurotrophic factors (BDNF, IGF)
4 Glial scar: CNS inflammation restriction
